FGFR2 and cholangiocarcinoma: The FGFR2 mutation V564F in the kinase domain conferred BGJ398 (infigratinib) resistance in cholangiocarcinoma FGFR2 fusion-positive patients (81) and the FGFR2-ASCL5 fusion (Ig2, I-set, a tyrosine kinase domain from FGFR2, and a truncated AMP-binding domain from ACSL5) was reported in post-progression biopsy of a patient with FGFR2-amplified gastric cancer with prior response to the FGFRi LY2874455 (82).